Jafron Biomedical Co Ltd
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification ma… Read more
Jafron Biomedical Co Ltd - Asset Resilience Ratio
Jafron Biomedical Co Ltd (300529) has an Asset Resilience Ratio of 36.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Jafron Biomedical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Jafron Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.03 Billion | 36.63% |
| Total Liquid Assets | CN¥2.03 Billion | 36.63% |
Asset Resilience Insights
- Very High Liquidity: Jafron Biomedical Co Ltd maintains exceptional liquid asset reserves at 36.63% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jafron Biomedical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jafron Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
FluroTech Ltd
OTCQB:FLURF |
Medical Devices | 0.00% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 0.50% |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
Annual Asset Resilience Ratio for Jafron Biomedical Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Jafron Biomedical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.02% | CN¥593.07 Million | CN¥5.38 Billion | +7.90pp |
| 2021-12-31 | 3.12% | CN¥150.01 Million | CN¥4.81 Billion | -4.57pp |
| 2016-12-31 | 7.69% | CN¥100.00 Million | CN¥1.30 Billion | -- |